SCHEMBL22401131

SCHEMBL22401131

Cc1c(C(=O)O)c2ccccc2n1C(C)C1CCC(=O)CC1

nearest known ligand 0.45

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ EZH2 Q15910 19/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22401128 1.00 EZH2 (0.45) EZH2
SCHEMBL23581333 0.87 EZH2 (0.49) EZH2
SCHEMBL29741552 0.87 EZH2 (0.49) EZH2
SCHEMBL23581335 0.87 EZH2 (0.49) EZH2
SCHEMBL22401114 0.86 EZH2 (0.55) EZH2
SCHEMBL22401116 0.86 EZH2 (0.55) EZH2
SCHEMBL16376979 0.85 EZH2 (0.55) EZH2
SCHEMBL22401126 0.85 EZH2 (0.55) EZH2
SCHEMBL16347078 0.85 EZH2 (0.55) EZH2
SCHEMBL16347077 0.85 EZH2 (0.55) EZH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115197194-A ZESTE enhancer homolog 2 inhibitors and uses thereof 四川海思科制药有限公司 2022-10-18 — — CN disclosed
US-11459315-B2 Modulators of methyl modifying enzymes, compositions and uses thereof CONSTELLATION PHARMACEUTICALS, INC. (US) 2022-10-04 — — US disclosed
EP-3707136-B1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF CONSTELLATION PHARMACEUTICALS INC (US) 2022-05-04 — — EP disclosed
US-20210230148-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF CONSTELLATION PHARMACEUTICALS, INC. 2021-07-29 — — US disclosed
EP-3707136-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF Constellation Pharmaceuticals, Inc. (US) 2020-09-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11459315-B2 Modulators of methyl modifying enzymes, compositions and uses thereof TPMT, TET1, TET2 EZH2 150/4885
US-20210230148-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF TPMT, TET1, TET2 EZH2 150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback